US 11896558
Use of an RXR agonist and taxanes in treating Her2+ cancers
granted A61KA61K31/015A61K31/192
Quick answer
US patent 11896558 (Use of an RXR agonist and taxanes in treating Her2+ cancers) held by The Board of Regents of the University of Texas System expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K31/015, A61K31/192, A61K31/216, A61K31/337